Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …

The diagnosis of Alzheimer's disease can be improved by the use of biological measures.
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …

The recent development of tau-specific positron emission tomography (PET) tracers enables
in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease …

The medial temporal lobe (MTL) is an early site of tau accumulation and MTL dysfunction
may underlie episodic-memory decline in aging and dementia. Postmortem data indicate …

Abnormal aggregation of tau in the brain is a major contributing factor in various
neurodegenerative diseases. The role of tau phosphorylation in the pathophysiology of …

The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-
associated tau protein characterizes 80% of all dementia disorders, the most common …

Tauvid has been approved by the US Food and Drug Administration (FDA) in 2020 for
positron emission tomography (PET) imaging of adult patients with cognitive impairments …

Tau PET imaging has potential for elucidating changes in the deposition of
neuropathological tau aggregates that are occurring during the progression of Alzheimer …

Fluorine is characterized by high electronegativity and small atomic size, which provide this
molecule with the unique property of augmenting the potency, selectivity, metabolic stability …

Purpose A limit on developing new treatments for a number of central nervous system (CNS)
disorders has been the inadequate understanding of the in vivo pathophysiology underlying …